Premium
Synergistic effect of the human GLP‐1 analogue liraglutide and a dual PPARα/γ agonist on glycaemic control in Zucker diabetic fatty rats
Author(s) -
Brand C. L.,
Galsgaard E. D.,
Tornehave D.,
Rømer J.,
Gotfredsen C. F.,
Wassermann K.,
Knudsen L. B.,
Vølund A.,
Sturis J.
Publication year - 2009
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2009.01049.x
Subject(s) - liraglutide , endocrinology , medicine , insulin , agonist , diabetes mellitus , glucagon like peptide 1 , glucose homeostasis , insulin resistance , type 2 diabetes , alpha cell , beta cell , receptor , islet
Aim/Hypothesis: Combination therapies are increasingly common in the clinical management of type 2 diabetes. We investigated to what extent combined treatment with the human glucagon‐like peptide‐1 (GLP‐1) analogue liraglutide and the dual PPARα/γ agonist ragaglitazar would improve glycaemic control in overtly diabetic Zucker diabetic fatty (ZDF) rats. Methods: Ninety overtly diabetic male ZDF rats were stratified into groups with matched haemoglobin A1c (HbA 1c ) (9.0 ± 0.1%). Liraglutide (15 and 50 μg/kg subcutaneously twice daily), ragaglitazar (1 and 3 mg/kg perorally once daily) and their vehicles were studied as monotherapy and in combination in a 3 × 3 factorial design. Results: After 4‐week treatment, synergistic effects on HbA 1c , non‐fasting morning blood glucose (BG) and/or 24‐h BG profiles were observed with three of the four combinations. The relationship between plasma insulin and BG in combination‐treated animals approached that of historical lean ZDF rats representing normal glucose homeostasis, suggesting that insulin secretion and insulin sensitivity were markedly improved. Increased insulin immunostaining in islets further supports the improved beta‐cell function and/or insulin sensitivity in combination‐treated animals. The synergistic effect on glycaemic control was found without a similar synergistic increase in beta‐cell mass in the combination groups. Conclusions/Interpretation: Our data demonstrate that combination treatment with a human GLP‐1 analogue and a dual PPARα/γ agonist through distinct mechanism of actions synergistically improves glycaemic control in the ZDF rat.